Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis.Several studies have evaluated the efficacy of PD-1/PD-L1 inhibitors in ovarian cancer; however, the response rate varies.  This study aims to explore the efficacy of anti-PD-1/PD-L1 therapy in ovarian cancer.  Single PD-1/PD-L1 inhibitors had the lowest ORR of 9% (95% CI: 7%, 12%), while the combination of PD-1/PD-L1 inhibitors and chemotherapy had the highest ORR of 36% (95% CI: 24%, 51%).  This study showed that PD-1/PD-L1 inhibitors alone have limited efficacy for ovarian cancer.  The combination of PD-1/PD-L1 inhibitors and chemotherapy could be chosen as the recommended modality for further study.
PD-1/PD-L1
A quantitative meta-analysis was performed through a systematic search in PubMed, Web of Science, and the Cochrane Library. 
PubMed
A quantitative meta-analysis was performed through a systematic search in PubMed, Web of Science, and the Cochrane Library. 
Web of Science
A quantitative meta-analysis was performed through a systematic search in PubMed, Web of Science, and the Cochrane Library. 
Cochrane Library